PLX Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of -2301.55%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 426.32%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 93.86%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Protalix Biotherapeutics, Inc. has a beta of -0.251, which suggesting that the stock is 125.1% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.292, suggesting its more volatile than the S&P 500 by 29.177%.

Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 30.07x while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 2.66x versus 51.34x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Denali Therapeutics, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of --. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat Denali Therapeutics, Inc.'s return on equity of -44.34%.

Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 426.32%. On the other hand Denali Therapeutics, Inc. has an analysts' consensus of $32.86 which suggests that it could grow by 56.99%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Denali Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Denali Therapeutics, Inc..

Protalix Biotherapeutics, Inc. has a beta of -0.251, which suggesting that the stock is 125.1% less volatile than S&P 500. In comparison Denali Therapeutics, Inc. has a beta of 1.046, suggesting its more volatile than the S&P 500 by 4.646%.

Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Denali Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. Denali Therapeutics, Inc. pays out -- of its earnings as a dividend.

Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are larger than Denali Therapeutics, Inc. quarterly revenues of --. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than Denali Therapeutics, Inc.'s net income of -$126.9M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 30.07x while Denali Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 2.66x versus 6.62x for Denali Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

OraSure Technologies, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of -50.63%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat OraSure Technologies, Inc.'s return on equity of -15.25%.

Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 426.32%. On the other hand OraSure Technologies, Inc. has an analysts' consensus of $4.50 which suggests that it could grow by 65.44%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than OraSure Technologies, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than OraSure Technologies, Inc..

Protalix Biotherapeutics, Inc. has a beta of -0.251, which suggesting that the stock is 125.1% less volatile than S&P 500. In comparison OraSure Technologies, Inc. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.858%.

Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OraSure Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. OraSure Technologies, Inc. pays out -- of its earnings as a dividend.

Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are smaller than OraSure Technologies, Inc. quarterly revenues of $27.1M. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than OraSure Technologies, Inc.'s net income of -$13.7M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 30.07x while OraSure Technologies, Inc.'s PE ratio is 26.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 2.66x versus 1.61x for OraSure Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PAVmed, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of -120220%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat PAVmed, Inc.'s return on equity of 8.75%.

Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 426.32%. On the other hand PAVmed, Inc. has an analysts' consensus of $9.50 which suggests that it could grow by 2495.63%. Given that PAVmed, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe PAVmed, Inc. is more attractive than Protalix Biotherapeutics, Inc..

Protalix Biotherapeutics, Inc. has a beta of -0.251, which suggesting that the stock is 125.1% less volatile than S&P 500. In comparison PAVmed, Inc. has a beta of 1.106, suggesting its more volatile than the S&P 500 by 10.577%.

Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. PAVmed, Inc. pays out -- of its earnings as a dividend.

Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are larger than PAVmed, Inc. quarterly revenues of $5K. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than PAVmed, Inc.'s net income of -$6M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 30.07x while PAVmed, Inc.'s PE ratio is 0.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 2.66x versus 5,129.46x for PAVmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.